Skip to main content


Presenter: Oliver Distler, University Hospital Zurich, Switzerland.

Wednesday 12 June: 16:15–17:45 (Abstract OP0017)

The phase III SENSCIS trial demonstrated that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated lung disease. However, the researchers found no significant improvements in other clinical outcomes with nintedanib treatment.

More on this trial